Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update

Radius Health (Nasdaq:RDUS), reported its financial results for the fourth quarter and full year ended December 31, 2017, and provided a business update.

As quoted in the press release:

“I’m also very pleased to announce that in January we aligned with the FDA on a regulatory path for our investigational abaloparatide patch, a novel technology with potential to provide a convenient, alternative treatment option for osteoporosis patients. This innovation is aimed at expanding both the abaloparatide and total anabolic addressable markets. We are also excited to announce that we have entered into a commercial supply agreement with 3M Company under which 3M has agreed to exclusively manufacture commercial supplies of abaloparatide patches,” Mr. Høiland continued.

Click here to read the full press release.